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INTRODUCTION
Infection is a major concern in the management of patients
with acute leukemia after cytotoxic chemotherapy (1-4).
Breeches in host defenses and immuno-compromised status
are inevitable consequences of cytotoxic chemotherapy as well
as of the underlying disease itself. Neutropenia is the major
problem in most patients who receive chemotherapy and can
predispose them to infection: at least half of the patients with
febrile neutropenia have infections (2).
Successful management of acute leukemia depends upon
appropriate control of the infectious complications. In order
to deal with such post-chemotherapeutic infectious compli-
cations, adequate assessment and prediction of the clinical
course are needed (5). In this study, we tried to identify the
prognostic factors influencing infection-associated mortality
in patients with acute leukemia.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of all acute
leukemic patients with febrile neutropenia following chemo-
therapy at the Catholic Hemopoietic Stem Cell Transplanta-
tion (HSCT) Center from January 1998 through December
1999. Antimicrobial prophylaxis consisted of ciprofloxacin
500 mg, roxithromycin 300 mg, fluconazole 50 mg p.o. daily
during the neutropenia.
An empirical antibiotic regimen was given to febrile patients
according to the guidelines of the Infectious Diseases Society
of America (IDSA) (4). If clinical, histopathological or radio-
logical signs suggested invasive fungal infection (IFI), anti-
fungal therapy consisting of intravenous infusion of conven-
tional or liposomal amphotericin B was initiated. The diag-
nosis of IFI was made on the basis of the definitions proposed
by the consensus group of the European Organization for
Research and Treatment of Cancer in conjunction with the
Mycoses Study Group (EORTC/MSG) (6).
Fever was defined as a single oral temperature of ≥38.3℃,
or a temperature of ≥38.0℃ for ≥1 hr. Neutropenia was
defined as a neutrophil count of less than 500/ L, or a count
of less than 1,000/ L with a predicted decrease to less than
500/ L (4, 7). 
The term microbiologically-defined infection (MDI) was
used if a clinically significant pathogen was identified from
a normally sterile specimen, or from an affected site, by cul-
ture or biopsy, whereas the term clinically-defined infection
(CDI) was employed if fever was accompanied by appropri-
ate clinical findings, for example, pulmonary infiltration or
inflammation of the skin or soft tissue. Fever was designat-
ed as “unexplained fever (UF)” when there was no clinical,
radiological or microbiological evidence of infection.
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We retrospectively reviewed the medical records of 284 patients with neutropenic
fever following chemotherapy for acute leukemia at the Catholic Hematopoietic
Stem Cell Transplantation Center from January 1998 to December 1999, to identi-
fy prognostic factors for infection-related mortality. Twenty-eight patients died of
infections. There was no difference in median age, gender ratio, or underlying dis-
ease between the dying and surviving groups. Bacteria were the main pathogens
following chemotherapy, and Gram positive organisms predominated in the dying
group. Pneumonia and sepsis were the main causes of death. There were 72 cases
of invasive fungal infection and their mortality was 27.8%. Invasive fungal infection
and previous history of fungal infection were independent prognostic factors for
outcome. Recovery from neutropenia was the significant protective factor for mor-
tality. In conclusion, the prognostic factors identified in this study could be useful
for deciding on more intensive treatment for those patients at greater risk of death.
To our knowledge, this is the first Korean study delineating prognostic factors in
acute leukemic patients with infectious complications.
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Baseline information included age, sex, and underlying
diseases. Patients who died due to infection were assigned
to the death group (DG) and the data of the DG were com-
pared to those of the surviving group (SG).
Statistical analyses were carried out with SPSS 10.0 (SPSS
Korea, Seoul, Korea), and prognostic factors were evaluated
by univariate and multivariate logistic regression analysis. P
values <0.05 were considered statistically significant. 
RESULTS
Demographic characteristics of patients 
We initially enrolled consecutively 326 patients with acute
leukemia from January 1998 through December 1999. As
42 of the patients did not have febrile episodes, 284 with
such episodes were eligible for the study.  Their median age
was 32.5 (15-68), and there were 179 males and 105 females.
Acute myelogenous leukemia (AML) was the most common
underlying disease (n=189, 66.5%), followed by acute lym-
phocytic leukemia (ALL; n=90, 31.7%). There were 4 cases
of biphenotype leukemia, and one case of undifferentiated
type.
One hundred and fifty-three patients (53.9%) received ini-
tial induction chemotherapy, while 131 (46.1%) received
reinduction chemotherapy. Acute myelogenous leukemia
(AML) was the predominant underlying diagnosis in both
groups, with no significant difference between them. There
was no significant difference in demographic characteristics
between the groups of dead and surviving patients (Table 1).
Microbiological characteristics
As shown in Table 2, the number of isolation of Gram-posi-
tive cocci (GPC) was comparable to that of Gram-negative
bacilli (GNB) (76 versus 74, respectively). GPCs were more
frequent in the DG and GNBs were slightly more frequent
in the SG, however, which was not statistically significant
(Z=1.531, p=0.629). Escherichia coli was the most common
GNB in the SG, whereas P. aeruginosa was the most common
organism in the DG (7% in SG vs. 19% in DG, p=0.04).
Staphylococci, streptococci, and enterococci were frequently
isolated GPCs in both groups. DG, dead group; SG, survived group; AML, acute myelogenous leuke-
mia; ALL, acute lymphocytic leukemia.
DG (n=28) SG (n=256)
Median age (range) (yr) 35 (18-61) 32 (15-68)
Gender ratio (male:female) 18:10 161:95
Underlying diagnosis
AML 17 (60.7%) 172 (67.2%)
ALL 11 (39.3%) 79 (30.9%)
Biphenotype 4  (1.6%)
Undifferentiated 1  (0.3%)
Table 1. Comparison of the general characteristics of dead and
survived patients
Organisms DG SG p
Bacteria
Gram positive cocci 11 (69%) 65 (49%) 0.63
Staphylococcus aureus 4 9 0.01
Coagulase (-) staphylococci 3 15 0.18
Alpha-hemolytic streptococci 4
viridans streptococci 16
Streptococcus pneumoniae 5
Enterococcus species 4 15 0.06
Corynebacterium jeikeium 1
Gram negative bacilli 5 (31%) 69 (51%) 0.63
Escherichia coli 37
Klebsiella pneumoniae 12
Pseudomonas aeruginosa 3 9 0.04
Aeromonas hydrophila 6
Enterobacter species 1 2
Citrobacter freundii 11
Acinetobacter baumannii 1
Morganella morganii 1
Fungus 3 4
Candida species 1 2
Aspergillus species 2 2
Virus 0 7
Herpes simplex virus 0 5
Varicella zoster virus 0 2
Table 2. Microbiological profiles
DG SG p
Type of infection
CDI 12 90
MDI 16 115
UF 51
Episode of fever before 8/28 (28.6%) 48/256 (18.8%)
chemotherapy
Median days to fever (range) 9 (1-17) 11 (1-29)
Median leukocyte count (/ L) 200 (100-900) 300 (100-900)
on onset
Episode of hypotension 6/28 (21.4%) 19/256 (7.4%) 0.013
Median days of antibiotics 16 (2-48) 14 (3-86)
administration
Previous fungal infection 3/28 (10.7%) 1/256 (0.4%) 0.001
Invasive fungal infection 20/28 (71.4%) 52/256 (20.3%) 0.001
Median days of antifungal 12.5 (1-35) 12 (3-79)
administration
Median dosage (mg) of 520 (39-2,140) 510 (85-3,180)
amphotericin-B 
Median days of neutropenia 19 (5-54) 17 (1-57)
Median febrile days 10 (2-27) 5 (1-61) 0.001
Recovery from neutropenia 7/28 (25.0%) 247/256 (96.5%) 0.001
CDI, clinically defined infection; MDI, microbiologically defined infec-
tion; UF, unexplained fever.
Table 3. Comparison of the clinical course of dead and survived
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Clinical course of patients
There were 102 cases of clinically-defined infection (CDI)
(35.9%), 131 of microbiologically-defined infection (MDI)
(46.1%), and 51 of unexplained fever (UF). Seventy-two
patients (25.4%) were diagnosed with invasive fungal infec-
tion on the basis of EORTC/MSG criteria. Median days from
neutropenia to the onset of fever, initial leukocyte count, dura-
tion of antibiotic treatment, duration of antifungal treatment,
total dosage of amphotericin-B, and duration of neutropenia
were not significantly different between DG and SG (Table 3).
More patients in the DG experienced episodes of hypotension
during their clinical course than those in SG (6/28, 21.4% vs.
19/256, 7.4%;  2=6.168, p=0.013). The incidence of inva-
sive fungal infection in the DG was higher than in the SG
(71.4% vs. 20.3%;  2=34.8; p=0.001). Median febrile peri-
od was greater in the DG than in the SG (10 vs. 5 days, p=
0.001). While 247 patients (96.5%) in the SG recovered from
neutropenia, only 25% of patients in the DG (n=7) did so
( 2=136.5, p=0.001). Four patients had prior fungal infec-
tions. Three of them developed invasive fungal infections
after the cytotoxic chemotherapy and all of them died. Over-
all, thirty-one patients died in hospital (mortality 11.0%).
Of these, 90.3% (28/31) were infection-related deaths. As
Table 4 indicates, pneumonia and sepsis were the most com-
mon causes of death. 
Evaluation of prognostic factors
We performed univariate and multivariate analysis to iden-
tify significant prognostic factor(s) using in-hospital infection-
related death as a dependent variable. A number of poten-
tial variables were evaluated. As Table 5 shows, episodes of
hypotension, previous fungal infection, invasive fungal infec-
tion, recovery from neutropenia, median days to fever, pneu-
monia, and total febrile days were selected as significant vari-
ables by univariate analysis. Multivariate analysis of these
variables finally selected three significant prognostic factors:
previous history of fungal infection, episodes of invasive fun-
gal infection, and recovery from neutropenia.
DISCUSSION
The inevitable deficit of host defense following chemothera-
py places most patients in danger of infectious complications
(1-4). As the clinical manifestations of infection in immuno-
compromised patients are in many respects different from
those in immunocompetent ones, detection and management
are almost always troublesome. For the successful treatment of
infection, knowledge of significant prognostic predictors is
important. There have been many reports of prognostic indi-
cators of infection (5, 8-12). However, as far as we know, this
is the first study of the prognostic factors of infectious compli-
cations in febrile neutropenic patients with acute leukemia
in Korea. 
Of the 284 patients in this study, 31 (10.9%) died. Most of
these (90.3%, 28/31) died as a result of infection. Pneumonia
and sepsis were the most common causes of death. Pneumo-
nia itself seemed to be a predictor of death in univariate anal-
ysis, but multivariate analysis failed to confirm this. Though
pneumonia is known to be an important infectious compli-
cation after chemotherapy (1, 13, 14), other factors could con-
tribute to a serious clinical outcome. 
The unique feature of the microbiological profile of the DG
was the predominance of Gram positive cocci (69%) com-
pared with SG. Over the last decade, there has been a shift
towards Gram positive cocci (GPC) from Gram negative bacilli
(GNB) as causative pathogens in immunocompromised hosts
(1, 15). In our data, numbers of GPC and GNB were nearly
equal, but there is a trend of steady increase in the frequency
of GPC in our institution, especially following HSCT (16,
17). With regard to Gram negative organisms, P. aeruginosa
was the major pathogen in the DG. As reported elsewhere
(1), patients with GNB infections usually had a poor prog-
*Disseminated invasive aspergillosis (Aspergillus flavus).
Infection-related
Pneumonia 13
Sepsis and/or multiorgan failure 12
Skin and soft tissue infection  1
Typhlitis    1
Disseminated fungal infection* 1
Non-infection related
Pulmonary hemorrhage 2
Ventricular arrhythmia 1
Table 4. Causes of death
Univariate analysis Multivariate analysis
O.R. (95% C.I.) O.R. (95% C.I.)
Episode of fever before 1.70 (0.70-4.20)
chemotherapy
Episode of hypotension 3.40 (1.20-9.40) 1.59 (0.31-8.25)
Bacteremia 0.34  (0.08-1.49)
Pneumonia  8.09 (3.46-18.90) 1.30 (0.27-6.29)
Pseudomonas aeruginosa 3.30 (0.84-12.96)
infection
Staphylococcal infection 2.04 (0.81-5.14)
Previous fungal infection 30.6 (3.1-305.2) 82.5 (3.0-243.8)
Invasive fungal infection 9.8 (4.1-23.5) 15.7 (2.8-86.7)
Recovery from neutropenia 0.04 (0.01-0.36) 0.01 (0.001-0.031)
Days to fever 1.15 (1.04-1.30) 1.03 (0.88-1.20)
Duration of antibiotics 1.03 (0.99-1.06)
Duration of antifungals 1.01 (0.97-1.05)
Total dosage of amphotericin-B 1.00 (0.99-1.01)
Days of neutropenia 1.03 (0.99-1.07)
Total febrile days 1.10 (1.04-1.15) 1.03 (0.95-1.11)
O.R., odd ratio; 95% C.I., 95% confidence interval.
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nosis. Among the GNBs, P. aeruginosa infection was partic-
ularly strongly associated with high mortality (18-20). In our
study, however, univariate analysis showed that Gram posi-
tive cocci and P. aeruginosa infection did not influence the prog-
nosis significantly, as indicated in Table 5.   
Viral infection was relatively rare, and all cases involved
herpes viruses. As the main defect in host immunity after
chemotherapy is in innate rather than adaptive immunity,
viral infection post-chemotherapy does not seem to be com-
mon or fatal.
Invasive fungal infection is probably the most fatal infec-
tious complication in febrile neutropenic patients (21, 22).
Among our patients, there were only 7 cases of microbiologi-
cally defined fungal infections. As the condition of febrile
neutropenic patients seldom permits invasive diagnostic pro-
cedures, it is hard to confirm fungal infections in suspicious
cases. Hence we used the EORTC/MSG criteria for invasive
fungal infections (IFIs) to identify 72 cases (proven 7, prob-
able 36, possible 29). The mortality of patients with IFI was
27.8% (20/52) and the incidence of IFI was much higher in
the DG than in the SG (71.4% vs. 20.3%; p=0.001). Four
patients had previous histories of IFI, and three of these suf-
fered a recurrence (1 proven rhinocerebral aspergillosis, 1 prob-
able, and 1 possible invasive aspergillosis) and all of them died.
These findings strongly suggest that invasive as well as pre-
vious fungal infections are important factors affecting out-
come. As both univariate and multivariate analysis showed,
these two variables were independent influences on the final
prognosis. However, dosage and duration of antifungal treat-
ment did not affect survival.  
Episodes of cardiovascular instability (hypotension) were
more frequent in the DG than the SG, but multivariate anal-
ysis failed to show that this variable was an independent prog-
nostic factor.
Neutropenia is the main defect in host defense after chemo-
therapy. As the neutrophil count and the duration of neu-
tropenia are closely related to susceptibility to infection (2,
23, 24), variables associated with neutropenia seemed likely
to affect the prognosis. In our study, although duration of
neutropenia did not differ significantly between the DG and
the SG, the neutrophil count was restored in fewer patients
in the DG than in the SG (25.0% vs. 96.5%; p=0.001). As
shown by the uni- and multivariate analysis, recovery from
neutropenia was the significant protective factor for survival.
In summary, fungal infection (previous as well as invasive)
and recovery from neutropenia were the main independent-
ly influential prognostic factors in acute leukemic patients
with infectious complications after chemotherapy. The prog-
nostic factors revealed in this study could help to identify
patients with an increased risk of dying, and more intensive
treatment focused on these factors could improve the out-
come of infectious complications.
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